Scribe Therapeutics
@scribetx.bsky.social
📅 Join today's Fierce Biotech Cell & Gene Turning Point event!
Our CEO @benjaminloakes.bsky.social will take the virtual stage at 11:30 am PT for a fireside chat exploring how CRISPR could redefine the treatment paradigm for CVD.
Register for free now: www.fiercecellandgene.com
Our CEO @benjaminloakes.bsky.social will take the virtual stage at 11:30 am PT for a fireside chat exploring how CRISPR could redefine the treatment paradigm for CVD.
Register for free now: www.fiercecellandgene.com
November 20, 2025 at 2:59 PM
📅 Join today's Fierce Biotech Cell & Gene Turning Point event!
Our CEO @benjaminloakes.bsky.social will take the virtual stage at 11:30 am PT for a fireside chat exploring how CRISPR could redefine the treatment paradigm for CVD.
Register for free now: www.fiercecellandgene.com
Our CEO @benjaminloakes.bsky.social will take the virtual stage at 11:30 am PT for a fireside chat exploring how CRISPR could redefine the treatment paradigm for CVD.
Register for free now: www.fiercecellandgene.com
We're excited to share breakthrough preclinical data across our cardiometabolic pipeline presented at #AHA25, highlighting our comprehensive strategy to address the key drivers of #ASCVD.
Thanks to Fierce Biotech‘s Darren Incorvaia for the feature:
www.fiercebiotech.com/research/scr...
Thanks to Fierce Biotech‘s Darren Incorvaia for the feature:
www.fiercebiotech.com/research/scr...
November 17, 2025 at 6:53 PM
We're excited to share breakthrough preclinical data across our cardiometabolic pipeline presented at #AHA25, highlighting our comprehensive strategy to address the key drivers of #ASCVD.
Thanks to Fierce Biotech‘s Darren Incorvaia for the feature:
www.fiercebiotech.com/research/scr...
Thanks to Fierce Biotech‘s Darren Incorvaia for the feature:
www.fiercebiotech.com/research/scr...
Scribe CEO @benjaminloakes.bsky.social will join a fireside chat at Fierce Biotech's Cell & Gene Turning Point event on Thursday, 11/20.
He'll discuss how CRISPR-based therapies could help prevent, not just treat, cardiovascular disease.
Register for free here: www.fiercecellandgene.com
He'll discuss how CRISPR-based therapies could help prevent, not just treat, cardiovascular disease.
Register for free here: www.fiercecellandgene.com
November 11, 2025 at 6:04 PM
Scribe CEO @benjaminloakes.bsky.social will join a fireside chat at Fierce Biotech's Cell & Gene Turning Point event on Thursday, 11/20.
He'll discuss how CRISPR-based therapies could help prevent, not just treat, cardiovascular disease.
Register for free here: www.fiercecellandgene.com
He'll discuss how CRISPR-based therapies could help prevent, not just treat, cardiovascular disease.
Register for free here: www.fiercecellandgene.com
#AHA25 Scientific Sessions are underway!
Don’t miss key presentations by CSO Aarif Khakoo and SVP of Discovery Biology Maria Mirotsou. From #CRISPR gene editing to epigenetic silencing, we’ll share updates on our pipeline of therapies for cardiovascular disease.👇
@ahascience.bsky.social
Don’t miss key presentations by CSO Aarif Khakoo and SVP of Discovery Biology Maria Mirotsou. From #CRISPR gene editing to epigenetic silencing, we’ll share updates on our pipeline of therapies for cardiovascular disease.👇
@ahascience.bsky.social
November 7, 2025 at 6:33 PM
#AHA25 Scientific Sessions are underway!
Don’t miss key presentations by CSO Aarif Khakoo and SVP of Discovery Biology Maria Mirotsou. From #CRISPR gene editing to epigenetic silencing, we’ll share updates on our pipeline of therapies for cardiovascular disease.👇
@ahascience.bsky.social
Don’t miss key presentations by CSO Aarif Khakoo and SVP of Discovery Biology Maria Mirotsou. From #CRISPR gene editing to epigenetic silencing, we’ll share updates on our pipeline of therapies for cardiovascular disease.👇
@ahascience.bsky.social
🥇 Our Computational Genomics & Data Science team won 1ST PLACE in AWS AI League for Startups SF!
Huge shout-out to champion Mohit Pandey and full squad for showcasing Scribe’s growing AI innovation capabilities. Thanks to @awscloud.bsky.social for inviting us and a fantastic competition.
Huge shout-out to champion Mohit Pandey and full squad for showcasing Scribe’s growing AI innovation capabilities. Thanks to @awscloud.bsky.social for inviting us and a fantastic competition.
November 5, 2025 at 8:31 PM
🥇 Our Computational Genomics & Data Science team won 1ST PLACE in AWS AI League for Startups SF!
Huge shout-out to champion Mohit Pandey and full squad for showcasing Scribe’s growing AI innovation capabilities. Thanks to @awscloud.bsky.social for inviting us and a fantastic competition.
Huge shout-out to champion Mohit Pandey and full squad for showcasing Scribe’s growing AI innovation capabilities. Thanks to @awscloud.bsky.social for inviting us and a fantastic competition.
📣 #AHA25 is almost here! We’re headed to New Orleans to share the latest on our pipeline of #CRISPR genome editing & epigenetic silencing therapies for cardiometabolic disease.
Details below on 4 presentations by our CSO Aarif Khakoo & SVP of Discovery Biology Maria Mirotsou 👇
Details below on 4 presentations by our CSO Aarif Khakoo & SVP of Discovery Biology Maria Mirotsou 👇
November 3, 2025 at 6:07 PM
When it’s spooky season at Scribe, expect our annual #Halloween barbecue, scary and scientific costumes, and treats galore. Happy Halloween to all! 🎃
November 1, 2025 at 12:21 AM
When it’s spooky season at Scribe, expect our annual #Halloween barbecue, scary and scientific costumes, and treats galore. Happy Halloween to all! 🎃
How can we transform the standard of care for heart disease? ❤️🩹
Join us at #TCT2025 this Saturday to hear from our CEO @benjaminloakes.bsky.social, who will share promising #CRISPR gene editing and epigenetic silencing strategies at @crfheart.bsky.social TCT MedTech Innovation Forum.
Join us at #TCT2025 this Saturday to hear from our CEO @benjaminloakes.bsky.social, who will share promising #CRISPR gene editing and epigenetic silencing strategies at @crfheart.bsky.social TCT MedTech Innovation Forum.
October 22, 2025 at 6:05 PM
How can we transform the standard of care for heart disease? ❤️🩹
Join us at #TCT2025 this Saturday to hear from our CEO @benjaminloakes.bsky.social, who will share promising #CRISPR gene editing and epigenetic silencing strategies at @crfheart.bsky.social TCT MedTech Innovation Forum.
Join us at #TCT2025 this Saturday to hear from our CEO @benjaminloakes.bsky.social, who will share promising #CRISPR gene editing and epigenetic silencing strategies at @crfheart.bsky.social TCT MedTech Innovation Forum.
Missed our presentation on Scribe’s ELXR (epigenetic editor) technology at #ESGCT2025?
Catch up with this BioWorld article highlighting how we engineered our ELXR platform for enhanced potency and its therapeutic application in durably targeting PCSK9.
www.bioworld.com/articles/725...
Catch up with this BioWorld article highlighting how we engineered our ELXR platform for enhanced potency and its therapeutic application in durably targeting PCSK9.
www.bioworld.com/articles/725...
Epigenetic approach shows durable PCSK9 silencing in primates
A preclinical study presented at the 32nd Annual Congress of the European Society of Gene and Cell Therapy (ESGCT), held in Seville Oct. 7-10, showed a new epigenetic editing technology that enables d...
www.bioworld.com
October 16, 2025 at 6:54 PM
Missed our presentation on Scribe’s ELXR (epigenetic editor) technology at #ESGCT2025?
Catch up with this BioWorld article highlighting how we engineered our ELXR platform for enhanced potency and its therapeutic application in durably targeting PCSK9.
www.bioworld.com/articles/725...
Catch up with this BioWorld article highlighting how we engineered our ELXR platform for enhanced potency and its therapeutic application in durably targeting PCSK9.
www.bioworld.com/articles/725...
Listen to Scribe’s co-founder, Jennifer Doudna, speak to the vision that Scribe was founded on – unlocking #CRISPR to revolutionize the standard of care for cardiometabolic disease.
"I really hope that gene editing technology, like CRISPR, becomes a preventative [therapy]..." 🧵
"I really hope that gene editing technology, like CRISPR, becomes a preventative [therapy]..." 🧵
October 10, 2025 at 6:42 PM
Listen to Scribe’s co-founder, Jennifer Doudna, speak to the vision that Scribe was founded on – unlocking #CRISPR to revolutionize the standard of care for cardiometabolic disease.
"I really hope that gene editing technology, like CRISPR, becomes a preventative [therapy]..." 🧵
"I really hope that gene editing technology, like CRISPR, becomes a preventative [therapy]..." 🧵
Congrats to our CEO, @benjaminloakes.bsky.social, on being named to BioSpace’s inaugural 40 Under 40 list of exemplary biotech leaders for his vision, innovation, and commitment to advancing next-generation #CRISPR-based therapeutics that improve patient outcomes.
October 7, 2025 at 4:32 PM
Congrats to our CEO, @benjaminloakes.bsky.social, on being named to BioSpace’s inaugural 40 Under 40 list of exemplary biotech leaders for his vision, innovation, and commitment to advancing next-generation #CRISPR-based therapeutics that improve patient outcomes.
We’re headed to #ESGCT2025 to share our latest #CRISPR #EpigeneticEditing data. Check out our presentation on Thursday, Oct. 9!
🧬 Engineering enhanced epigenetic editors: novel repressor domains drive potent and durable therapeutic gene silencing in non-human primates
🧬 Engineering enhanced epigenetic editors: novel repressor domains drive potent and durable therapeutic gene silencing in non-human primates
October 6, 2025 at 5:01 PM
We’re headed to #ESGCT2025 to share our latest #CRISPR #EpigeneticEditing data. Check out our presentation on Thursday, Oct. 9!
🧬 Engineering enhanced epigenetic editors: novel repressor domains drive potent and durable therapeutic gene silencing in non-human primates
🧬 Engineering enhanced epigenetic editors: novel repressor domains drive potent and durable therapeutic gene silencing in non-human primates
Meet Scribe at #CGMesa25 in Phoenix 🌵
Our CFO David Parrot will be onsite at the @alliancerm.bsky.social Cell & Gene Meeting on the Mesa to present updates on our work engineering #CRISPR-based medicines for cardiometabolic disease.
Swing by and learn more on Monday, Oct. 6 at 1:45pm MST.
Our CFO David Parrot will be onsite at the @alliancerm.bsky.social Cell & Gene Meeting on the Mesa to present updates on our work engineering #CRISPR-based medicines for cardiometabolic disease.
Swing by and learn more on Monday, Oct. 6 at 1:45pm MST.
October 3, 2025 at 7:40 PM
Meet Scribe at #CGMesa25 in Phoenix 🌵
Our CFO David Parrot will be onsite at the @alliancerm.bsky.social Cell & Gene Meeting on the Mesa to present updates on our work engineering #CRISPR-based medicines for cardiometabolic disease.
Swing by and learn more on Monday, Oct. 6 at 1:45pm MST.
Our CFO David Parrot will be onsite at the @alliancerm.bsky.social Cell & Gene Meeting on the Mesa to present updates on our work engineering #CRISPR-based medicines for cardiometabolic disease.
Swing by and learn more on Monday, Oct. 6 at 1:45pm MST.
Ahead of #WorldHeartDay, Taylor Swift recently raised an important reminder: heart disease is the leading cause of death, and one person dies from it every 34 seconds.
For some, including her father, a routine stress test revealed severe disease early enough to undergo surgery.
For some, including her father, a routine stress test revealed severe disease early enough to undergo surgery.
September 30, 2025 at 12:25 AM
Ahead of #WorldHeartDay, Taylor Swift recently raised an important reminder: heart disease is the leading cause of death, and one person dies from it every 34 seconds.
For some, including her father, a routine stress test revealed severe disease early enough to undergo surgery.
For some, including her father, a routine stress test revealed severe disease early enough to undergo surgery.
Attending the Genome Editing Therapeutics Summit?
Join us Sept. 30 for the opening presentation by Kai-Yuan Chen, Scribe's Director of Data Science & Tech Platform, highlighting DeepXE: our deep learning model powering #CRISPR-CasX therapeutic gRNA design.
#AI #MachineLearning
Join us Sept. 30 for the opening presentation by Kai-Yuan Chen, Scribe's Director of Data Science & Tech Platform, highlighting DeepXE: our deep learning model powering #CRISPR-CasX therapeutic gRNA design.
#AI #MachineLearning
September 26, 2025 at 5:04 PM
Attending the Genome Editing Therapeutics Summit?
Join us Sept. 30 for the opening presentation by Kai-Yuan Chen, Scribe's Director of Data Science & Tech Platform, highlighting DeepXE: our deep learning model powering #CRISPR-CasX therapeutic gRNA design.
#AI #MachineLearning
Join us Sept. 30 for the opening presentation by Kai-Yuan Chen, Scribe's Director of Data Science & Tech Platform, highlighting DeepXE: our deep learning model powering #CRISPR-CasX therapeutic gRNA design.
#AI #MachineLearning
An important piece in @forbes.com by Leaps By Bayer highlighting the dangers of high cholesterol, the urgent need for solutions beyond statins, and Scribe’s advances developing #CRISPR gene editing and epigenetic silencing therapies for cardiometabolic disease.
www.forbes.com/sites/juerge...
www.forbes.com/sites/juerge...
Treating High Cholesterol Could Become A One-And-Done Treatment
Gene editing and epigenetic silencing offer two ways of changing the basic biology of cholesterol for future treatments beyond statins.
www.forbes.com
September 25, 2025 at 4:31 PM
An important piece in @forbes.com by Leaps By Bayer highlighting the dangers of high cholesterol, the urgent need for solutions beyond statins, and Scribe’s advances developing #CRISPR gene editing and epigenetic silencing therapies for cardiometabolic disease.
www.forbes.com/sites/juerge...
www.forbes.com/sites/juerge...
This Thursday, join us at the Oppenheimer Private Life Science Company Showcase for a virtual presentation by our CFO David Parrot.
📅 September 25, 2025
🕗 3:15pm ET
📍 Virtual
✅ Register for the event or reach out to our team at www.scribetx.com/contact
📅 September 25, 2025
🕗 3:15pm ET
📍 Virtual
✅ Register for the event or reach out to our team at www.scribetx.com/contact
September 23, 2025 at 5:00 PM
This Thursday, join us at the Oppenheimer Private Life Science Company Showcase for a virtual presentation by our CFO David Parrot.
📅 September 25, 2025
🕗 3:15pm ET
📍 Virtual
✅ Register for the event or reach out to our team at www.scribetx.com/contact
📅 September 25, 2025
🕗 3:15pm ET
📍 Virtual
✅ Register for the event or reach out to our team at www.scribetx.com/contact
Knowing your #cholesterol could save your life. This National #CholesterolEducationMonth, stay up to date on the impact cholesterol levels have on your risk for heart disease. 👇
September 19, 2025 at 4:25 PM
Knowing your #cholesterol could save your life. This National #CholesterolEducationMonth, stay up to date on the impact cholesterol levels have on your risk for heart disease. 👇
Attending the Bank of America Healthcare Trailblazers Private Company Conference in Boston this week?
Book a meeting with Scribe CFO David Parrot to learn about our latest updates, data, and approach to advancing #CRISPR for cardiometabolic disease 👉 www.scribetx.com/contact
Book a meeting with Scribe CFO David Parrot to learn about our latest updates, data, and approach to advancing #CRISPR for cardiometabolic disease 👉 www.scribetx.com/contact
September 16, 2025 at 4:00 PM
Attending the Bank of America Healthcare Trailblazers Private Company Conference in Boston this week?
Book a meeting with Scribe CFO David Parrot to learn about our latest updates, data, and approach to advancing #CRISPR for cardiometabolic disease 👉 www.scribetx.com/contact
Book a meeting with Scribe CFO David Parrot to learn about our latest updates, data, and approach to advancing #CRISPR for cardiometabolic disease 👉 www.scribetx.com/contact
📣 Presenting new breakthrough data from two of our core platforms 📣
We're proud to showcase the success of our Lp(a)-lowering therapy STX-1200 and novel #AI platform, DeepXE, for next-generation #CRISPR-based therapeutics.
More details in our link below 👇
We're proud to showcase the success of our Lp(a)-lowering therapy STX-1200 and novel #AI platform, DeepXE, for next-generation #CRISPR-based therapeutics.
More details in our link below 👇
September 9, 2025 at 4:09 PM
📣 Presenting new breakthrough data from two of our core platforms 📣
We're proud to showcase the success of our Lp(a)-lowering therapy STX-1200 and novel #AI platform, DeepXE, for next-generation #CRISPR-based therapeutics.
More details in our link below 👇
We're proud to showcase the success of our Lp(a)-lowering therapy STX-1200 and novel #AI platform, DeepXE, for next-generation #CRISPR-based therapeutics.
More details in our link below 👇
At Scribe, we run on teamwork and purpose – in and out of the lab.
#JPMCC 2025 marked our 4th year participating in the global J.P. Morgan Corporate Challenge. Check out our reel for highlights our team captured as they ran through San Francisco, repping our “ELXR” tech! 🧪😉
#JPMCC 2025 marked our 4th year participating in the global J.P. Morgan Corporate Challenge. Check out our reel for highlights our team captured as they ran through San Francisco, repping our “ELXR” tech! 🧪😉
September 8, 2025 at 6:30 PM
At Scribe, we run on teamwork and purpose – in and out of the lab.
#JPMCC 2025 marked our 4th year participating in the global J.P. Morgan Corporate Challenge. Check out our reel for highlights our team captured as they ran through San Francisco, repping our “ELXR” tech! 🧪😉
#JPMCC 2025 marked our 4th year participating in the global J.P. Morgan Corporate Challenge. Check out our reel for highlights our team captured as they ran through San Francisco, repping our “ELXR” tech! 🧪😉
If you’ll be in New York for the Cantor Global Healthcare Conference, our CEO @benjaminloakes.bsky.social and CFO David Parrot will be on site and available for one-on-one meetings between Sept. 3-5.
Interested in connecting? Reach out through our website 👉 www.scribetx.com/contact
Interested in connecting? Reach out through our website 👉 www.scribetx.com/contact
September 2, 2025 at 4:01 PM
If you’ll be in New York for the Cantor Global Healthcare Conference, our CEO @benjaminloakes.bsky.social and CFO David Parrot will be on site and available for one-on-one meetings between Sept. 3-5.
Interested in connecting? Reach out through our website 👉 www.scribetx.com/contact
Interested in connecting? Reach out through our website 👉 www.scribetx.com/contact
At #ESCCongress for the latest on #CRISPR gene editing treatments for cardiometabolic disease?
On Monday, our CSO Aarif Khakoo will present late-breaking preclinical data on STX-1200, our novel CRISPR-CasX based gene editing therapy to reduce elevated Lp(a) & CVD risk. Read more 👇
On Monday, our CSO Aarif Khakoo will present late-breaking preclinical data on STX-1200, our novel CRISPR-CasX based gene editing therapy to reduce elevated Lp(a) & CVD risk. Read more 👇
August 29, 2025 at 4:03 PM
At #ESCCongress for the latest on #CRISPR gene editing treatments for cardiometabolic disease?
On Monday, our CSO Aarif Khakoo will present late-breaking preclinical data on STX-1200, our novel CRISPR-CasX based gene editing therapy to reduce elevated Lp(a) & CVD risk. Read more 👇
On Monday, our CSO Aarif Khakoo will present late-breaking preclinical data on STX-1200, our novel CRISPR-CasX based gene editing therapy to reduce elevated Lp(a) & CVD risk. Read more 👇
This fall, we are thrilled to present our latest updates on our #CRISPR genetic and epigenetic editing therapies, new machine learning approach, and corporate strategy at several premier conferences.
If you’ll be at #ECCongress, #CGMesa25, and others, read on for more details 👇
If you’ll be at #ECCongress, #CGMesa25, and others, read on for more details 👇
August 25, 2025 at 1:07 PM
This fall, we are thrilled to present our latest updates on our #CRISPR genetic and epigenetic editing therapies, new machine learning approach, and corporate strategy at several premier conferences.
If you’ll be at #ECCongress, #CGMesa25, and others, read on for more details 👇
If you’ll be at #ECCongress, #CGMesa25, and others, read on for more details 👇
What does it take to rewrite the story of disease? Our CEO @benjaminloakes.bsky.social shared with @bigthink.com how a mission-driven team like Scribe can redefine what is possible in medicine with #CRISPR.
His insights on leadership, innovation, and bold vision 👇
bigthink.com/business/lea...
His insights on leadership, innovation, and bold vision 👇
bigthink.com/business/lea...
Leadership essentials: “Inspire, motivate, and cultivate”
Benjamin Oakes — CEO of therapeutic biotech company Scribe Therapeutics — joins Big Think for a chat about innovation and more.
bigthink.com
August 22, 2025 at 6:22 PM
What does it take to rewrite the story of disease? Our CEO @benjaminloakes.bsky.social shared with @bigthink.com how a mission-driven team like Scribe can redefine what is possible in medicine with #CRISPR.
His insights on leadership, innovation, and bold vision 👇
bigthink.com/business/lea...
His insights on leadership, innovation, and bold vision 👇
bigthink.com/business/lea...